Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety profile and efficacy of whole brain
radiotherapy (WBRT) concomitantly with temozolomide (TMZ) in patients with brain metastases
(BM).Patients with BM were randomly assigned to 30 Gy of WBRT with or without concomitant TMZ
(75 mg/m2/d) plus two cycles of TMZ (200 mg/m2/d for 5 days).